Synergy Pharmaceuticals

Synergy Pharmaceuticals was a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases, especially conditions involving impaired bowel function. Their main product was linaclotide, used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company aimed to improve patients' quality of life by providing targeted therapies that address underlying digestive issues. In 2015, Synergy was acquired by Alfa Wassermann, and its products continue to be used in the management of certain digestive disorders.